# Subsense BCI **Aliases:** Subsense; Subsense Inc.; @subsenseBCI **Domain:** Brain-Computer Interfaces / Neurotechnology / Nanotechnology / Human-Machine Convergence **Doc Type:** Institution and Technology Node **Maturity:** Developed **Epistemic State:** Company, personnel, and announced roadmap documented; platform remains preclinical ## Definition **Subsense Inc. is a Palo Alto neurotechnology company developing NanoBCI, a proposed non-surgical, nanoparticle-mediated brain-computer-interface platform.** The company describes a modular architecture combining functional nanoparticles with wearable wireless hardware to read and stimulate neural activity. Subsense's public roadmap places the work in preclinical development. Its site projects clinical pilots for 2027–2029, a possible clinical product in 2029–2031, and consumer BCI applications after 2031. Subsense also states that its products are not authorized, cleared, or approved by the FDA for U.S. marketing and that performance claims have not been evaluated by the FDA. ## Nanotechnology and neuropharmacology first Subsense should be analyzed first as a **nanotechnology, neuropharmacology, and molecular-interface problem**, and only secondarily as a conventional BCI company. Its strategic discontinuity is the movement of part of the interface away from permanently implanted electronics and toward administered functional material inside the biological substrate: - intranasal administration; - biodistribution and blood-brain-barrier transit; - targeted localization; - plasmonic nanoparticles for optical neural readout; - magnetoelectric nanoparticles for externally driven local neuromodulation; and - wearable hardware as the external energizing, interrogating, and computational layer. That architecture must eventually be evaluated with device and pharmacological vocabulary together: dose, delivery route, tissue distribution, targeting, residence time, repeat dosing, clearance or degradation, toxicity, immunogenicity, tissue accumulation, reversibility, and persistence. Subsense's current materials describe goals and preliminary laboratory work; they do not settle these translational questions. ## N3, MOANA, and Merge genealogy [[wiki/DARPA N3|DARPA N3]] and Rice's [[wiki/MOANA|MOANA]] project are publicly documented ancestors of the broader design pattern: nonsurgical or minutely invasive neural access, temporary nanotransducers or biologically delivered components, external optical/acoustic/electromagnetic transceivers, and bidirectional read-write objectives. This is an architectural genealogy, not proof that Subsense received MOANA technology or descends organizationally from the Rice program. [[wiki/Merge Labs|Merge Labs]] belongs on the same longitudinal route through its biology-device-AI approach and announced ultrasound-on-chip development platform. The three implementations remain technically distinct. ## Kurzweil convergence The connection to [[wiki/Ray Kurzweil|Ray Kurzweil]] is now institutional rather than merely thematic: - Subsense lists **John-Clark Levin**, Research Lead at Kurzweil Technologies, as a product advisor. - On September 3, 2026, Subsense announced that **Ray Kurzweil had joined as Product and Vision Advisor**, advising on long-range product and technology development and the convergence of AI with neural interfaces. The appointment documents advisory participation and a shared horizon of AI-neural convergence. It is not experimental validation of NanoBCI or evidence that the proposed system has succeeded in humans. ## Lorimer network route Bryant first identified `@subsenseBCI` and `@LorimerVentures` as an unusual X-network adjacency. The reviewed public record does not establish a direct [[wiki/Lorimer Ventures|Lorimer Ventures]] investment in Subsense. A more concrete one-degree professional path nevertheless exists: **Lorimer Ventures → Formic ← Lux Capital / Shahin Farshchi → Subsense Annual Forum.** Formic's 2022 Series A announcement identifies Lorimer Ventures as a participant, Lux Capital as lead investor, and Shahin Farshchi as a new board member. Farshchi later participated in Subsense's September 2026 forum. His relevance is unusually specific: he co-authored a 2006 IEEE paper describing a wireless neural interface. This is a documented network bridge, not evidence of a hidden cap-table relationship or coordinated X-account activity. ## Blackrock Neurotech bridges The relation to [[wiki/Blackrock Neurotech|Blackrock Neurotech]] is stronger than ordinary industry adjacency and runs through at least two independent functions: - **Lindsey Jardine**, a former Blackrock Vice President of Clinical and Regulatory, is Subsense's Regulatory Advisor and is described by Subsense as leading its FDA TAP Pilot and Breakthrough-neurotechnology strategies. - **Sergey Stavisky**, a Subsense Scientific Advisor, conducts human neural-decoding research using Blackrock NeuroPort hardware and has BCI intellectual property licensed to Blackrock. Jardine carries clinical-regulatory experience; Stavisky carries scientific, signal, hardware, and IP experience. Together they place Subsense inside a shared developmental ecology with the mature invasive benchmark it seeks to approach without conventional surgery. They do not establish a Blackrock investment in Subsense or validate Subsense's nanoparticle platform. Upstream, [[wiki/Tether Evo|Tether Evo]] is Blackrock's majority owner following a $200 million investment in 2024 and is developing local-first neural-speech decoding through BrainWhisperer and QVAC. The conservative route is **Tether Evo → Blackrock Neurotech → Jardine / Stavisky → Subsense**, not Tether → Subsense. ## Continuity significance Subsense occupies the proposed interface between machine intelligence as an external computational service and machine intelligence as part of the addressable human cognitive environment. If systems of this class eventually become safe, bidirectional, and high-bandwidth, they could become infrastructure for [[wiki/Human-Machine Symbiosis|Human-Machine Symbiosis]], memory augmentation, synthetic sensory channels, and [[wiki/Consciousness Continuity Infrastructure|Consciousness Continuity Infrastructure]]. Those are prospective implications, not present capabilities. ## Routes [[wiki/Ray Kurzweil|Ray Kurzweil]] · [[wiki/Lorimer Ventures|Lorimer Ventures]] · [[wiki/Blackrock Neurotech|Blackrock Neurotech]] · [[wiki/Tether Evo|Tether Evo]] · [[wiki/DARPA N3|DARPA N3]] · [[wiki/MOANA|MOANA]] · [[wiki/Merge Labs|Merge Labs]] · [[wiki/Neural Interfaces and Continuity Architecture|Neural Interfaces and Continuity Architecture]] · [[wiki/Human-Machine Symbiosis|Human-Machine Symbiosis]] · [[wiki/Consciousness Continuity Infrastructure|Consciousness Continuity Infrastructure]] · [[wiki/Machine Succession|Machine Succession]] · [[wiki/Cicada 3301|Cicada 3301]] ## Sources / Provenance - Subsense, [NanoBCI technology and development milestones](https://subsense-bci.com/technology/). - Subsense, [Team, collaborators, and advisors](https://subsense-bci.com/about-us/). - Subsense via Business Wire, [Ray Kurzweil joins Subsense as Product and Vision Advisor](https://markets.financialcontent.com/worldnow/article/bizwire-2026-9-3-ai-visionary-ray-kurzweil-joins-subsense-as-product-and-vision-advisor), September 3, 2026. - Formic, [Formic's Series A Raise](https://formic.co/resources/articles/formics-series-a-raise), January 18, 2022. - PubMed, [A TinyOS-enabled MICA2-based wireless neural interface](https://pubmed.ncbi.nlm.nih.gov/16830946/), IEEE Transactions on Biomedical Engineering, July 2006. - DARPA, [Six Paths to the Nonsurgical Future of Brain-Machine Interfaces](https://www.darpa.mil/news/2019/nonsurgical-brain-machine-interfaces), May 20, 2019. - Rice University, [Feds fund creation of headset for high-speed brain link](https://news.rice.edu/news/2019/feds-fund-creation-headset-high-speed-brain-link), May 20, 2019. - Blackrock Neurotech, [Tether invested $200M in Blackrock Neurotech](https://blackrockneurotech.com/insights/tether-invested-200m-in-blackrock-neurotech-accelerating-development-and-commercialization-of-implantable-bci-technology/), April 29, 2024. - Bryant-supplied network-convergence and molecular-interface research memoranda, September 7, 2026 — source of the original X-adjacency observation, multi-path topology, and longitudinal framing.